Overview

Study to Evaluate the Efficacy and Safety of MY008211A in Subjects with Primary Immunoglobulin a Nephropathy (IgAN)

Status:
NOT_YET_RECRUITING
Trial end date:
2028-01-31
Target enrollment:
Participant gender:
Summary
Efficacy and safety of MY008211A in IgAN patients
Phase:
PHASE2
Details
Lead Sponsor:
Wuhan Createrna Science and Technology Co., Ltd